Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.57 |
| ▸ | DNASE1 | P24855 | 1/20 | 0.57 |
| ▸ | FEN1 | P39748 | 1/20 | 0.57 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | MAT2A | P31153 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243461 | 0.82 | ERCC1 (0.51) | MEN1KMT2AL3MBTL1LMNAERCC1 | |
| SCHEMBL5243007 | 0.82 | ERCC1 (0.51) | MEN1KMT2AL3MBTL1LMNAERCC1 | |
| SCHEMBL5857905 | 0.81 | MAPK9 (0.56) | MEN1KMT2AL3MBTL1LMNAERCC1 | |
| SCHEMBL14339623 | 0.81 | LMNA (0.55) | MEN1KMT2ALMNAERCC1DNASE1 | |
| SCHEMBL5243046 | 0.78 | ERCC1 (0.52) | MEN1KMT2AL3MBTL1LMNAERCC1 | |
| SCHEMBL18934335 | 0.77 | MEN1 (0.68) | MEN1KMT2AL3MBTL1LMNAALDH1A1 | |
| SCHEMBL5241978 | 0.77 | PGR (0.57) | MEN1KMT2ALMNAERCC1DNASE1 | |
| SCHEMBL15396849 | 0.77 | MEN1 (0.68) | MEN1KMT2AL3MBTL1LMNAALDH1A1 | |
| SCHEMBL28738835 | 0.77 | MEN1 (1.00) | MEN1KMT2AL3MBTL1LMNAALDH1A1 | |
| SCHEMBL5718587 | 0.77 | MEN1 (0.68) | MEN1KMT2AL3MBTL1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115644-B2 | Heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-10-03 | — | — | US | claimed |
| EP-1539708-B1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1539708-B1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7115644-B2 | Heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1539708-A1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040192748-A1 | Heterocyclic compounds | BOEHRINGER INGELHEIM PARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004024699-A1 | BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192748-A1 | Heterocyclic compounds | IL1B, CCL5, IL4 | MEN1 3627/4885KMT2A 4023/4885L3MBTL1 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.